For instance, T2D adult patients treated with the IL-1β RA anakinra presented ameliorated glucose levels and pancreatic function with decreased systemic inflammation markers such as CRP and IL6 (Larsen et al., 2007) and similar results were observed with the use of IL-1β neutralizing antibody Gevokizumab (Cavelti-Weder et al., 2012). Here, IL1B is linked to type 2 diabetes mellitus.